HemaCell is a new cell therapy company to regenerate hematopoietic lineages in vitro, with unique stem cell reprogramming.
Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish a platform using platelet cells as a drug delivery carrier.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 27, 2022 | Series A | — | 7 | — | — | Detail |
Feb 25, 2022 | Seed | ¥100M | 8 | CMB International Capital Corporation Northern Light Venture Capital | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
CMB International Capital Corporation | Yes | Seed |
Northern Light Venture Capital | Yes | Seed |
Tairong Capital | — | Series A |
Guanfang Capital | — | Series A |
Country Garden Venture Capital | — | Series A |
Founder H Fund | — | Series A |
Laurel Venture Capital | — | Series A |
Lucion | — | Series A |
WeDo Capital Management | — | Series A |
Junzilan Capital | — | Seed |